[Noncoronary dilated cardiomyopathy after reverse remodeling heart surgery]

Kardiologiia. 2013;53(12):41-6.
[Article in Russian]

Abstract

We present here analysis of surgical treatment of 24 patients (5 women, 19 men, age 20-75, mean age 50.7 +/- 2.5 years) with dilated cardiomyopathy (DCM) operated during the period from 2008 to 2013. Duration of the disease ranged from 4 months to 12 years (mean 49.4 +/- 7.5 months). According to symptoms and results of 6-minute walk test 3 patients (13%) had heart failure NYHA class III and 21 patients (87%)--NYHA class IV. Average end-diastolic left ventricular size was 7.4 +/- 0.18 cm (6.0-9.2 cm), ejection fraction--26.7 +/- 2.1% (13-47%), mean pulmonary artery pressure 54.9 +/- 2.9 mm Hg (35-80 mmHg). All patients underwent organ-conserving surgery aimed at reverse remodeling of the heart. Surgery was accompanied with implantation of implantable cardioverter defibrillator in 3 patients and/or cardiac resynchronization therapy device in 6 patients. Two patients (8.3%) died during hospitalization of hemodynamically significant ventricular arrhythmias; seven patients (29.2%) died in the late postoperative period. The results of the analysis indicate that reverse-remodeling surgery may be effective in patients with DCM of any age group with preserved reserves of the liver, kidney, and lung function in the absence of active myocarditis. Further observations are needed to determine the place of this operation in the protocol of treatment of patients with DCM.

Publication types

  • English Abstract

MeSH terms

  • Arrhythmias, Cardiac* / etiology
  • Arrhythmias, Cardiac* / mortality
  • Cardiac Resynchronization Therapy
  • Cardiac Surgical Procedures* / adverse effects
  • Cardiac Surgical Procedures* / instrumentation
  • Cardiac Surgical Procedures* / methods
  • Cardiac Surgical Procedures* / mortality
  • Cardiomyopathy, Dilated / classification
  • Cardiomyopathy, Dilated / drug therapy
  • Cardiomyopathy, Dilated / physiopathology
  • Cardiomyopathy, Dilated / surgery*
  • Cardiovascular Agents / therapeutic use
  • Defibrillators, Implantable
  • Female
  • Follow-Up Studies
  • Heart Function Tests / methods
  • Humans
  • Male
  • Middle Aged
  • Moscow / epidemiology
  • Organ Sparing Treatments / methods
  • Postoperative Complications / mortality*
  • Postoperative Period
  • Survival Analysis
  • Treatment Outcome

Substances

  • Cardiovascular Agents